261 related articles for article (PubMed ID: 11001329)
1. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent.
Projan SJ
Pharmacotherapy; 2000 Sep; 20(9 Pt 2):219S-223S; discussion 224S-228S. PubMed ID: 11001329
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).
Petersen PJ; Jacobus NV; Weiss WJ; Sum PE; Testa RT
Antimicrob Agents Chemother; 1999 Apr; 43(4):738-44. PubMed ID: 10103174
[TBL] [Abstract][Full Text] [Related]
3. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases.
Biedenbach DJ; Beach ML; Jones RN
Diagn Microbiol Infect Dis; 2001 Aug; 40(4):173-7. PubMed ID: 11576790
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.
Gales AC; Jones RN
Diagn Microbiol Infect Dis; 2000 Jan; 36(1):19-36. PubMed ID: 10744364
[TBL] [Abstract][Full Text] [Related]
5. The glycylcyclines: a comparative review with the tetracyclines.
Zhanel GG; Homenuik K; Nichol K; Noreddin A; Vercaigne L; Embil J; Gin A; Karlowsky JA; Hoban DJ
Drugs; 2004; 64(1):63-88. PubMed ID: 14723559
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America.
Gales AC; Jones RN; Andrade SS; Pereira AS; Sader HS
Braz J Infect Dis; 2005 Oct; 9(5):348-56. PubMed ID: 16410885
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines.
Testa RT; Petersen PJ; Jacobus NV; Sum PE; Lee VJ; Tally FP
Antimicrob Agents Chemother; 1993 Nov; 37(11):2270-7. PubMed ID: 8285606
[TBL] [Abstract][Full Text] [Related]
8. Recent developments in tetracycline antibiotics.
Sum PE; Sum FW; Projan SJ
Curr Pharm Des; 1998 Apr; 4(2):119-32. PubMed ID: 10197036
[TBL] [Abstract][Full Text] [Related]
9. Tigecycline - how powerful is it in the fight against antibiotic-resistant bacteria?
Seputiene V; Povilonis J; Armalyte J; Suziedelis K; Pavilonis A; Suziedeliene E
Medicina (Kaunas); 2010; 46(4):240-8. PubMed ID: 20571291
[TBL] [Abstract][Full Text] [Related]
10. Tigecycline: first of a new class of antimicrobial agents.
Rose WE; Rybak MJ
Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
[TBL] [Abstract][Full Text] [Related]
11. GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteria.
Deshpande LM; Gales AC; Jones RN
Int J Antimicrob Agents; 2001 Jul; 18(1):29-35. PubMed ID: 11463523
[TBL] [Abstract][Full Text] [Related]
12. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.
Boucher HW; Wennersten CB; Eliopoulos GM
Antimicrob Agents Chemother; 2000 Aug; 44(8):2225-9. PubMed ID: 10898710
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.
Fritsche TR; Kirby JT; Jones RN
Diagn Microbiol Infect Dis; 2004 Jul; 49(3):201-9. PubMed ID: 15246511
[TBL] [Abstract][Full Text] [Related]
14. Tigecycline: a glycylcycline antimicrobial agent.
Doan TL; Fung HB; Mehta D; Riska PF
Clin Ther; 2006 Aug; 28(8):1079-1106. PubMed ID: 16982286
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
Patel R; Rouse MS; Piper KE; Steckelberg JM
Diagn Microbiol Infect Dis; 2000 Nov; 38(3):177-9. PubMed ID: 11109018
[TBL] [Abstract][Full Text] [Related]
16. Tigecyclin--the first glycylcycline to undergo clinical development: an overview of in vitro activity compared to tetracycline.
Felmingham D
J Chemother; 2005 Aug; 17 Suppl 1():5-11. PubMed ID: 16285353
[TBL] [Abstract][Full Text] [Related]
17. Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines.
Tuckman M; Petersen PJ; Projan SJ
Microb Drug Resist; 2000; 6(4):277-82. PubMed ID: 11272255
[TBL] [Abstract][Full Text] [Related]
18. New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors.
Chopra I
Drug Resist Updat; 2002; 5(3-4):119-25. PubMed ID: 12237079
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain.
Betriu C; Rodríguez-Avial I; Sánchez BA; Gómez M; Alvarez J; Picazo JJ;
Antimicrob Agents Chemother; 2002 Mar; 46(3):892-5. PubMed ID: 11850282
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens.
Goldstein EJ; Citron DM; Merriam CV; Warren Y; Tyrrell K
Antimicrob Agents Chemother; 2000 Oct; 44(10):2747-51. PubMed ID: 10991855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
